Global Adrenocortical Carcinoma Drugs Market 2021: Global Industry Analysis Report to 2027
The global adrenocortical carcinoma drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). One of the key factors that are primarily driving the growth of the market includes the comparative advantages of novel drugs over chemotherapeutics. Chemotherapeutics such as mitotane can cause major side effects including peripheral neuropathy and seizures. This is expected to increase the use of novel drugs, which show long-term efficacy and potential benefits in patients.
Another key factor driving the market growth includes the
rising advancements in imaging techniques for detecting tumors and adrenal
lesions. Various imaging techniques with enhanced diagnostic accuracy as a
non-invasive approach have been developed for adrenocortical carcinoma. For
instance, the multiphase computed tomography technique is one of the latest
imaging techniques which can calculate both the absolute percentage and the
relative percentage washout, which helps in identifying both benign and malignant
lesions of the adrenal gland. Thus, advances in imaging techniques for adrenal
tumors is anticipated to fuel the growth of the global adrenocortical carcinoma
drugs market during the forecast period.
To Request a Sample of our Report on Global
Adrenocortical Carcinoma Drugs Market: https://www.omrglobal.com/request-sample/adrenocortical-carcinoma-drugs-market
Some key players operating in the market include Bristol-Myers Squibb
Co., Merck & Co., Inc., and Laboratoire HRA-Pharma SAS, among others.
These players are eyeing on strengthening their position in the market by
adopting various strategies as mergers and acquisitions, partnerships,
collaborations, new product launch and development in the existing product
portfolio, and so on. For instance, in November 2021, Merck announced that
KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the Japan
Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line treatment
of patients with radically unresectable, advanced or recurrent esophageal
carcinoma in combination with chemotherapy (5-fluorouracil [5-FU] plus
cisplatin) based on data from the Phase 3 KEYNOTE-590 trial.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: Bristol-Myers
Squibb Co., Merck & Co., Inc., and Laboratoire HRA-Pharma SAS, among others
(Get 15% Discount on Buying this Report)
A
full Report of Global Adrenocortical Carcinoma Drugs Market is Available
at: https://www.omrglobal.com/industry-reports/adrenocortical-carcinoma-drugs-market
Global Adrenocortical Carcinoma Drugs Market by Segment
By Type
• Chemotherapy
• Targeted therapy
By Application
• Hospital
• Research Institute
• Clinic
• Other
Global Adrenocortical Carcinoma Drugs Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment